Your browser is no longer supported. Please, upgrade your browser.
ELOX Eloxx Pharmaceuticals, Inc. daily Stock Chart
ELOX [NASD]
Eloxx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.36 Insider Own0.10% Shs Outstand40.07M Perf Week-7.99%
Market Cap109.50M Forward P/E- EPS next Y-0.83 Insider Trans0.00% Shs Float35.64M Perf Month-16.03%
Income-52.90M PEG- EPS next Q-0.21 Inst Own52.60% Short Float3.70% Perf Quarter30.91%
Sales- P/S- EPS this Y8.10% Inst Trans0.06% Short Ratio9.34 Perf Half Y-62.06%
Book/sh0.66 P/B4.36 EPS next Y13.50% ROA-83.60% Target Price- Perf Year-69.23%
Cash/sh1.16 P/C2.49 EPS next 5Y- ROE-129.90% 52W Range1.44 - 9.59 Perf YTD-60.87%
Dividend- P/FCF- EPS past 5Y44.90% ROI- 52W High-69.55% Beta2.48
Dividend %- Quick Ratio4.10 Sales past 5Y- Gross Margin- 52W Low102.78% ATR0.28
Employees29 Current Ratio4.10 Sales Q/Q- Oper. Margin- RSI (14)47.92 Volatility9.41% 9.99%
OptionableYes Debt/Eq0.54 EPS Q/Q-4.90% Profit Margin- Rel Volume0.49 Prev Close2.88
ShortableYes LT Debt/Eq0.36 EarningsMay 07 AMC Payout- Avg Volume141.28K Price2.92
Recom2.00 SMA20-4.92% SMA50-5.74% SMA200-26.23% Volume12,757 Change1.39%
Jun-11-20Downgrade Citigroup Buy → Neutral
Sep-06-19Initiated Janney Buy $14
Dec-24-18Initiated H.C. Wainwright Neutral $10
Jul-03-18Initiated Citigroup Buy
Jun-18-20 11:14AM  
10:42AM  
Jun-17-20 04:01PM  
Jun-11-20 12:06PM  
May-27-20 12:48PM  
May-08-20 03:01PM  
May-07-20 04:01PM  
Apr-21-20 12:37PM  
Apr-20-20 09:24AM  
Apr-13-20 07:30AM  
Apr-06-20 10:53AM  
Mar-25-20 09:00AM  
Mar-10-20 01:45PM  
Mar-05-20 04:00PM  
02:30PM  
Feb-26-20 04:00PM  
Jan-14-20 02:30PM  
Dec-27-19 06:38AM  
Dec-24-19 07:45AM  
Dec-22-19 06:41PM  
Dec-18-19 07:00AM  
Dec-11-19 05:09PM  
Dec-06-19 07:43AM  
Nov-19-19 07:00AM  
Nov-18-19 07:00AM  
Nov-07-19 10:00AM  
Nov-05-19 04:01PM  
Oct-31-19 12:15PM  
Oct-23-19 12:18PM  
Oct-10-19 08:41AM  
Sep-23-19 07:30AM  
Sep-16-19 07:30AM  
Sep-13-19 07:48PM  
Sep-10-19 07:30AM  
Aug-26-19 09:30AM  
Aug-13-19 10:01AM  
Aug-08-19 12:51PM  
Aug-07-19 07:30AM  
Aug-05-19 08:00AM  
Jul-31-19 12:12PM  
Jul-17-19 07:30AM  
Jun-24-19 04:01PM  
Jun-20-19 08:36AM  
07:25AM  
Jun-19-19 04:01PM  
Jun-10-19 08:00AM  
Jun-06-19 04:27PM  
01:34PM  
12:30PM  
May-27-19 11:10AM  
May-21-19 12:50PM  
May-19-19 09:29PM  
May-09-19 02:50PM  
07:00AM  
May-02-19 10:30AM  
Apr-22-19 09:37AM  
Apr-15-19 01:15PM  
Apr-11-19 02:45PM  
12:07PM  
Mar-27-19 09:00AM  
Mar-26-19 12:11PM  
Mar-20-19 12:19PM  
Mar-12-19 11:35PM  
Mar-08-19 11:39AM  
07:00AM  
Mar-05-19 09:08AM  
Feb-26-19 04:02PM  
Feb-20-19 04:00PM  
Feb-19-19 07:00AM  
Feb-14-19 08:40AM  
Feb-13-19 11:12AM  
Feb-04-19 07:00AM  
Jan-03-19 01:08PM  
Dec-20-18 02:54PM  
Dec-19-18 05:37AM  
Dec-17-18 08:39PM  
Nov-20-18 07:00AM  
Nov-19-18 07:00AM  
Nov-08-18 07:00AM  
Oct-18-18 11:49AM  
Oct-16-18 06:16PM  
Sep-24-18 07:00AM  
Aug-07-18 04:01PM  
Jul-18-18 07:30AM  
Jul-17-18 07:30AM  
Jun-25-18 04:20PM  
Jun-18-18 07:30AM  
Jun-11-18 07:30AM  
Jun-08-18 11:00AM  
May-10-18 04:01PM  
May-01-18 01:27PM  
Apr-30-18 04:01PM  
Apr-27-18 12:41PM  
Apr-25-18 06:22PM  
Apr-24-18 04:01PM  
Apr-18-18 11:30AM  
Mar-19-18 07:00AM  
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel ribonucleic acid for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which has completed Phase 1 clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.